Quantcast

Latest Levodopa-Induced Dyskinesia Stories

2014-06-16 16:25:13

EMERYVILLE, Calif., June 16, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time. The presentation will be webcast live and available for replay from the Adamas website at http://ir.adamaspharma.com/events.cfm in the Investor Relations section until, July 8, 2014. About...

2014-06-10 08:31:23

EMERYVILLE, Calif., June 10, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. In order to...

2014-06-09 16:25:29

EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 8,741,343 entitled "Method Of Administering Amantadine Prior To A Sleep Period." The claims of this patent are directed towards administration, prior to bedtime, of certain formulations of amantadine HCl, including Adamas' lead product ADS-5102 and similar amantadine-based products. "This is the...

2014-06-09 16:25:26

EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced today that it has initiated a pivotal Phase 3 clinical study of ADS-5102 (amantadine HCl), a high-dose, controlled-release version of amantadine for the treatment of patients with Parkinson's disease who have developed levodopa-induced dyskinesia (LID). LID is a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals...

2014-05-29 16:26:44

EMERYVILLE, Calif., May 29, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced a poster presentation at the 18(th) International Congress of Parkinson's Disease and Movement Disorders from June 8 to 12, 2014, in Stockholm, Sweden. The poster (abstract #722) is titled "Rater training and data completeness in the study of ADS-5102 in levodopa-induced dyskinesia (EASED study)." The poster presentation will take place during the poster session "Parkinson's...

2014-04-30 08:33:57

Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phase 2/3 EASED study, included...

2014-04-23 16:30:11

EMERYVILLE, Calif., April 23, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66(th) Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA. http://photos.prnewswire.com/prnvar/20130618/LA33709LOGO The poster (4009), is titled, "Safety and Efficacy Study of ADS-5102 (amantadine HCl) extended release capsules in Levodopa-Induced Dyskinesia...

2014-01-29 12:27:59

NEW YORK, Jan. 29, 2014 /PRNewswire-USNewswire/ -- Research projects from three biopharmaceutical companies in the United States comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders...

2014-01-08 23:04:51

Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, and Adamas Pharmaceuticals Inc., today announced an agreement for Phase 3 clinical trials manufacturing of ADS-5102 (amantadine HCl) extended release capsules, an investigational treatment being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease. Somerset, NJ (PRWEB) January 08, 2014 Catalent Pharma...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related